Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      SOPHiA GENETICS Reports First Quarter 2026 Results

      SOPHiA GENETICS Logo (PRNewsfoto/SOPHiA GENETICS)

      News provided by

      SOPHiA GENETICS

      May 05, 2026, 06:45 ET

      Share this article

      Share this article


      BOSTON and ROLLE, Switzerland, May 5, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, today reported financial results for the first quarter ended March 31, 2026.

      First Quarter 2026 Financial Results

      • Revenue was $21.7 million, up 22% year-over-year
      • Gross margin was 68.0% on a reported basis and 75.4% on an adjusted basis, compared to 68.7% reported and 75.7% adjusted in the prior year period
      • IFRS net loss was $19.3 million, an increase of 11% year-over-year; Adjusted EBITDA loss was $9.2 million, improving 3% year-over-year

      "We started 2026 strong, delivering 22% year-over-year revenue growth and a record 108,000 genomic analyses on SOPHiA DDMTM," said Jurgi Camblong, PhD., Chief Executive Officer and Co-Founder of SOPHiA GENETICS. "Demand for our platform continues to grow, as U.S. hospitals and laboratories increasingly look to launch Ai-powered precision medicine capabilities, and customers across the globe continue to show strong interest in new applications such as Liquid Biopsy and Enhanced Exomes."

      Camblong added, "Looking ahead, new business momentum remains strong. Exciting new applications, continued U.S. expansion, and rising interest from BioPharma provide major catalysts for future growth. Accelerating growth, in combination with our strong gross margin performance and persistent focus on operational excellence, position us well to deliver meaningful operating leverage as the year progresses."

      Business Highlights

      Expanding with existing customers

      • Performed a record 108,000 analyses on SOPHiA DDMTM, representing 16% year-over-year volume growth
      • Delivered strong analysis volume growth in the U.S. and Asia Pacific (APAC) with 28% and 31% year-over-year growth, respectively; Europe and Middle East (EMEA) revenue was up 30% in the period
      • Expanded our footprint with existing customers as Net Dollar Retention increased to 117% in Q1 2026, up from 103% in Q1 2025
      • Signed three notable expansion deals in EMEA, each valued over $1 million per year, as existing customers continue to add new applications, in addition to continued expand momentum in the U.S.
      • Reached 537 core genomics customers as of March 31, 2026, up from 490 customers a year ago

      Landing new customers to fuel future growth

      • Signed 18 new core genomic customers in Q1 2026, which are expected to begin generating revenue over the next twelve months
      • Continued to sign premier healthcare institutions across the globe, including CHU Bordeaux's Haut Lévêque Hospital, one of France's major university hospitals, for HemOnc; Maastricht UMC, a leading Dutch academic medical center, for MSK-ACCESS® powered with SOPHiA DDMTM; and Christian Medical College, one of India's most prestigious medical institutions, for HemOnc

      Accelerating growth in the U.S. market

      • Achieved 28% year-over-year U.S. analysis volume growth in Q1 2026
      • Announced an expanded partnership with Mount Sinai Health System, one of the leading academic health systems in the U.S., which is adopting SOPHiA DDMTM for HemOnc and Solid Tumor testing; Mount Sinai joins a growing network of New York-area partners, including NYU Langone Health and Memorial Sloan Kettering Cancer Center
      • Signed Protean BioDiagnostics, a Florida-based cancer diagnostics company, which is adopting SOPHiA DDMTM for Solid Tumor testing

      Scaling growth with new applications

      • Reached a total of 100 customers across 30+ countries signed-to-adopt the Liquid Biopsy application MSK-ACCESS® or the Solid Tumor application MSK-IMPACT®, less than two years after launch
      • Performed nearly 3,000 Liquid Biopsy analyses in Q1 2026, up 100%+ year-over-year, as customers implement the application and begin to ramp usage
      • Signed major new customers to the Liquid Biopsy application MSK-ACCESS® powered with SOPHiA DDMTM, including Ospedale Niguarda, one of Italy's leading hospitals in Milan; Ruhr University Bochum in Germany; and King Abdullah International Medical Center in Saudi Arabia

      Building BioPharma partnerships

      • Continued to build momentum with BioPharma partners around evidence generation, sponsored deployment projects, and commercialization and co-development of future companion diagnostic (CDx) offerings
      • Delivered positive BioPharma revenue growth in Q1, modestly accretive to the company's overall growth rate, as several recently signed new projects begin generating revenue

      Driving operational excellence

      • Achieved a 75.4% adjusted gross margin in Q1 2026 by continuing to optimize compute costs and leverage the scale of the cloud-native SOPHiA DDMTM platform
      • Executed targeted cost actions in April, modestly reducing headcount and operating spend as Ai-driven productivity improvements enabled us to streamline workflows while maintaining investment in key growth areas
      • Reaffirmed commitment to profitable growth, expecting to approach adjusted EBITDA breakeven by the end of 2026 and cross over to positive adjusted EBITDA in the second half of 2027

      2026 Financial Outlook

      Based on information as of today, SOPHiA GENETICS is reaffirming the following guidance:

      • Full year revenue between $92 million and $94 million, representing approximately 20% to 22% year-over-year growth compared to FY 2025
      • Adjusted EBITDA loss between $29 million and $32 million, compared to $41.5 million in FY 2025

      Earnings Call and Webcast Information

      SOPHiA GENETICS will host a conference call and live webcast to discuss the first quarter 2026 results on Tuesday, May 5, 2026, at 8:00 a.m. (08:00) Eastern Time / 2:00 p.m. (14:00) Central European Time. The call will be webcast live on the SOPHiA GENETICS Investor Relations website, ir.sophiagenetics.com. Additionally, an audio replay of the conference call will be available on the SOPHiA GENETICS website after its completion.

      Non-IFRS Financial Measures

      Other than with respect to revenue, the Company only provides guidance on a non-IFRS basis. The Company does not provide a reconciliation of forward-looking adjusted gross margin (non-IFRS measure) to gross margin (the most comparable IFRS financial measure), due to the inherent difficulty in forecasting and quantifying amortization of capitalized research & development expenses that are necessary for such reconciliation. In addition, the Company does not provide a reconciliation of forward-looking adjusted EBITDA (non-IFRS measure) to loss for the period (the most comparable IFRS financial measure), due to the inherent difficulty in forecasting and quantifying depreciation expense, amortization of capitalized research & development expenses and intangible assets, interest income, interest expense, fair value adjustments on warrants, income taxes, foreign exchange gains or losses, share-based compensation expenses, social charges on share-based compensation, the non-cash portion of pensions paid in excess of actual contributions, certain transaction costs and litigation expenses that are necessary for such reconciliation.

      To provide investors with additional information regarding the company's financial results, SOPHiA GENETICS has disclosed here and elsewhere in this earnings release the following non-IFRS measures:

      • Adjusted gross profit, which the company calculates as revenue minus cost of revenue adjusted to exclude amortization of capitalized research and development expenses;
      • Adjusted gross profit margin, which the company calculates as adjusted gross profit as a percentage of revenue;
      • Adjusted EBITDA, which the company calculates as loss for the period before depreciation, amortization, interest income, interest expense, fair value adjustments on warrant obligations, foreign exchange (losses) gains, net, income tax (expense) benefit, share-based compensation expense, social charges on share-based compensation, non-cash pension expenses, certain transaction costs and litigation expenses.

      These non-IFRS measures are key measures used by SOPHiA GENETICS management and board of directors to evaluate its operating performance and generate future operating plans. The exclusion of certain expenses facilitates operating performance comparability across reporting periods by removing the effect of non-cash expenses and certain variable charges. Accordingly, the company believes that these non-IFRS measures provide useful information to investors and others in understanding and evaluating its operating results in the same manner as its management and board of directors.

      These non-IFRS measures have limitations as financial measures, and you should not consider them in isolation or as a substitute for analysis of SOPHiA GENETICS' results as reported under IFRS. Some of these limitations are:

      • These non-IFRS measures exclude the impact of depreciation. Although depreciation is a non-cash charge, the assets being depreciated may need to be replaced in the future and these non-IFRS measures do not reflect capital expenditure requirements for such replacements or for new capital expenditures;
      • These non-IFRS measures exclude the impact of interest expense. Interest expense will continue to be for the foreseeable future a recurring expense based on the company's financial liabilities;
      • These non-IFRS measures exclude the impact of interest income. Interest income will continue to be for the foreseeable future recurring income based on the company's financial assets;
      • These non-IFRS measures exclude the impact of income taxes. Income taxes will continue to be for the foreseeable future a recurring expense incurred in the various jurisdictions in which the company operates;
      • These non-IFRS measures exclude the impact of foreign exchange gains (losses),net. Foreign exchange gains and losses will continue to be for the foreseeable future a recurring expense incurred as the company participates in transactions outside of the company's functional currency;
      • These non-IFRS measures exclude the impact of fair value adjustments of warrant obligations. Fair value adjustments on warrant obligations will continue to be for the foreseeable future a recurring expense incurred as the company has outstanding warrant obligations;
      • These non-IFRS measures exclude the impact of amortization of capitalized research and development expenses and intangible assets. Amortization of these assets will continue to be for the foreseeable future a recurring expense incurred as the Company continues to invest in developing revenue-generating products through research and development. Although amortization is a non-cash charge, the assets being amortized may need to be replaced in the future and these non-IFRS measures do not reflect capital expenditure requirements for such replacements or for new capital expenditures;
      • These non-IFRS measures exclude the impact of share-based compensation expenses. Share-based compensation has been, and will continue to be for the foreseeable future, a recurring expense in the company's business and an important part of its compensation strategy;
      • These non-IFRS measures exclude the impact of social charges related to share-based compensation. These social charges have been, and will continue to be for the foreseeable future, a recurring expense in the company's business;
      • These non-IFRS measures exclude the impact of the non-cash portion of pensions paid in excess of actual contributions to match actuarial expenses. Pension expenses have been, and will continue to be for the foreseeable future, a recurring expense in the business;
      • These non-IFRS measures exclude the impact of certain capital markets transaction costs. These costs may occur from time to time in the future as needed to complete the transactions;
      • These non-IFRS measures exclude the impact of litigation expenses related to the company's defense of lawsuits filed by Guardant Health. These expenses are expected to continue for the duration of the litigation and may increase in future periods;and
      • Other companies, including companies in the company's industry, may calculate these non-IFRS measures differently, which reduces their usefulness as comparative measures.

      Because of these limitations, you should consider these non-IFRS measures alongside other financial performance measures, including various cash flow metrics, net income and other IFRS results.

      The tables below provide the reconciliation of the most comparable IFRS measures to the non-IFRS measures for the periods presented.

      Presentation of Constant Currency Revenue

      SOPHiA GENETICS operates internationally, and its revenues are generated primarily in the U.S. dollar, the euro and Swiss franc and, to a lesser extent, British pound, Australian dollar, Brazilian real, Turkish lira and Canadian dollar depending on the company's customers' geographic locations. Changes in revenue include the impact of changes in foreign currency exchange rates. We present the non-IFRS financial measure "constant currency revenue" (or similar terms such as constant currency revenue growth) to show changes in revenue without giving effect to period-to-period currency fluctuations. Under IFRS, revenues received in local (non-U.S. dollar) currencies are translated into U.S. dollars at the average monthly exchange rate for the month in which the transaction occurred. When the company uses the term "constant currency", it means that it has translated local currency revenues for the current reporting period into U.S. dollars using the same average foreign currency exchange rates for the conversion of revenues into U.S. dollars that we used to translate local currency revenues for the comparable reporting period of the prior year. The company then calculates the difference between the IFRS revenue and the constant currency revenue to yield the "constant currency impact" for the current period.

      The company's management and board of directors use constant currency revenue growth to evaluate growth and generate future operating plans. The exclusion of the impact of exchange rate fluctuations provides comparability across reporting periods and reflects the effects of customer acquisition efforts and land-and-expand strategy. Accordingly, it believes that this non-IFRS measure provides useful information to investors and others in understanding and evaluating revenue growth in the same manner as the management and board of directors. However, this non-IFRS measure has limitations, particularly as the exchange rate effects that are eliminated could constitute a significant element of its revenue and could significantly impact performance and prospects. Because of these limitations, you should consider this non-IFRS measure alongside other financial performance measures, including revenue and revenue growth presented in accordance with IFRS and other IFRS results.

      The table below provides the reconciliation of the most comparable IFRS growth measures to the non-IFRS growth measures for the current period.

      About SOPHiA GENETICS

      SOPHiA GENETICS (Nasdaq: SOPH) is an Ai-native healthcare technology company on a mission to transform patient care by expanding access to data-driven medicine globally. It is the creator of SOPHiA DDM™, an Ai platform that analyzes complex genomic and multimodal data to generate real-time, real-world insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.

      Forward-Looking Statements

      This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding SOPHiA GENETICS future results of operations and financial position, business strategy, products and technology, partnerships and collaborations, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on SOPHiA GENETICS' management's beliefs and assumptions and on information currently available to the company's management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in the company's filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of its date. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in the company's expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

      SOPHiA GENETICS SA

      Interim Condensed Consolidated Statements of Loss

      (Amounts in USD thousands, except per share data)

      (Unaudited)




      Three months ended March 31,



      2026


      2025

      Revenue


      $          21,688


      $          17,779

      Cost of revenue


      (6,939)


      (5,571)

      Gross profit


      14,749


      12,208

      Research and development costs


      (9,460)


      (9,118)

      Selling and marketing costs


      (8,813)


      (7,534)

      General and administrative costs


      (13,759)


      (11,600)

      Other operating income, net


      —


      8

      Operating loss


      (17,283)


      (16,036)

      Interest income


      289


      450

      Interest expense


      (1,667)


      (659)

      Fair value adjustments on warrant obligations


      (92)


      (38)

      Foreign exchange losses, net


      (316)


      (599)

      Loss before income taxes


      (19,069)


      (16,882)

      Income tax expense


      (253)


      (503)

      Loss for the period


      (19,322)


      (17,385)

      Attributable to the owners of the parent


      (19,322)


      (17,385)






      Basic and diluted loss per share


      $            (0.27)


      $            (0.26)

      SOPHiA GENETICS SA

      Interim Condensed Consolidated Statements of Comprehensive Loss

      (Amounts in USD thousands)

      (Unaudited)




      Three months ended March 31,



      2026


      2025

      Loss for the period


      $        (19,322)


      $        (17,385)

      Other comprehensive (loss) income:





      Items that may be reclassified to statement of loss





      Currency translation adjustments


      (530)


      2,586

      Total items that may be reclassified to statement of loss


      (530)


      2,586

      Items that will not be reclassified to statement of loss (net of tax)





      Remeasurement of defined benefit plans


      123


      47

      Total items that will not be reclassified to statement of loss


      123


      47

      Other comprehensive (loss) income for the period


      $            (407)


      $           2,633

      Total comprehensive loss for the period


      $        (19,729)


      $        (14,752)

      Attributable to owners of the parent


      $        (19,729)


      $        (14,752)

      SOPHiA GENETICS SA

      Interim Condensed Consolidated Balance Sheets

      (Amounts in USD thousands)

       (Unaudited)




      March 31, 2026


      December 31, 2025

      Assets





      Current assets





      Cash and cash equivalents


      $                65,392


      $                70,289

      Accounts receivable


      14,312


      15,001

      Inventory


      7,086


      6,351

      Prepaids and other current assets


      9,021


      7,438

      Total current assets


      95,811


      99,079

      Non-current assets





      Property and equipment


      5,096


      5,665

      Intangible assets


      35,824


      35,891

      Right-of-use assets


      11,701


      12,382

      Deferred tax assets


      1,813


      1,831

      Other non-current assets


      6,750


      8,183

      Total non-current assets


      61,184


      63,952

      Total assets


      $               156,995


      $               163,031

      Liabilities and equity





      Current liabilities





      Accounts payable


      $                12,668


      $                  8,960

      Accrued expenses


      13,437


      20,736

      Deferred contract revenue


      15,946


      16,720

      Lease liabilities, current portion


      2,713


      2,700

      Warrant obligations


      1,831


      1,412

      Total current liabilities


      46,595


      50,528

      Non-current liabilities





      Borrowings


      47,844


      47,733

      Lease liabilities, net of current portion


      11,868


      12,587

      Defined benefit pension liabilities


      4,098


      4,162

      Other non-current liabilities


      902


      876

      Total non-current liabilities


      64,712


      65,358

      Total liabilities


      111,307


      115,886

      Equity





      Share capital


      4,814


      4,814

      Share premium


      488,423


      473,675

      Treasury shares


      (1,007)


      (1,218)

      Other reserves


      92,056


      89,150

      Accumulated deficit


      (538,598)


      (519,276)

      Total equity


      45,688


      47,145

      Total liabilities and equity


      $               156,995


      $               163,031

      SOPHiA GENETICS SA

      Interim Condensed Consolidated Statements of Cash Flows

      (Amounts in USD thousands)

      (Unaudited)




      Three months ended March 31,



      2026


      2025

      Operating activities





      Loss before tax


      $               (19,069)


      $               (16,882)

      Adjustments for non-monetary items





      Depreciation


      1,079


      985

      Amortization


      1,672


      1,312

      Finance expense, net


      1,426


      925

      Fair value adjustments on warrant obligations


      92


      38

      Expected credit loss allowance increase (reversal)


      30


      (20)

      Share-based compensation


      3,313


      3,835

      Movements in provisions and pensions


      25


      57

      Research tax credit


      (173)


      (172)

      Loss on disposal of property and equipment


      3


      —

      Working capital changes





      Decrease (increase) in accounts receivable


      469


      (2,961)

      Decrease (increase) in prepaids and other assets


      189


      393

      Decrease (increase) in inventory


      (867)


      972

      Increase (decrease) in accounts payables, accrued expenses,
      deferred contract revenue, and other liabilities


      (3,275)


      813

      Cash used in operating activities


      (15,086)


      (10,705)

      Income tax paid


      (34)


      (45)

      Net cash flows used in operating activities


      (15,120)


      (10,750)

      Investing activities





      Purchase of property and equipment


      (878)


      —

      Acquisition of intangible assets


      (32)


      (46)

      Capitalized development costs


      (1,960)


      (1,445)

      Interest received


      289


      452

      Net cash flow used in investing activities


      (2,581)


      (1,039)

      Financing activities





      Proceeds from exercise of share options


      463


      40

      Interest paid


      (1,348)


      (567)

      Proceeds from sale of common stock in at-the-market offering,
      net of transaction costs


      14,496


      —

      Payments of principal portion of lease liabilities


      (569)


      (463)

      Net cash flow provided by/(used in) financing activities


      13,042


      (990)

      Increase (decrease) in cash and cash equivalents


      (4,659)


      (12,779)

      Effect of exchange differences on cash balances


      (238)


      1,081

      Cash and cash equivalents at beginning of the period


      70,289


      80,226

      Cash and cash equivalents at end of the period


      $                65,392


      $                68,528

      SOPHiA GENETICS SA

      Reconciliation of IFRS Net Loss to Adjusted EBITDA

      (Amounts in USD thousands)

      (Unaudited)




      Three months ended March 31,



      2026


      2025

      IFRS loss for the period


      $         (19,322)


      $         (17,385)

      Exclude the impact of:





      Depreciation


      $            1,079


      $               985

      Amortization(3)(4)


      1,672


      1,312

      Interest income


      (289)


      (450)

      Interest expense


      1,667


      659

      Fair value adjustments on warrant obligations


      92


      38

      Foreign exchange losses (gains), net


      316


      599

      Income tax expense


      253


      503

      Share-based compensation expense(1)


      3,313


      3,835

      Social charges related to share-based compensation(7)


      1,068


      355

      Non-cash pension expense(2)


      91


      86

      Transaction costs(5)


      168


      —

      Litigation expenses(6)


      689


      —

      Adjusted EBITDA


      $           (9,203)


      $           (9,463)

      SOPHiA GENETICS SA

      Reconciliation of IFRS Revenue Growth to Constant Currency Revenue Growth

      (Amounts in USD thousands, except for %)

      (Unaudited)




      Three months ended March 31,



      2026


      2025


      Growth

      IFRS revenue


      $    21,688


      $    17,779


      22 %

      Current period constant currency impact


      (1,482)


      —



      Constant currency revenue


      $    20,206


      $    17,779


      14 %

      SOPHiA GENETICS SA

      Reconciliation of IFRS to Adjusted Gross Profit and Gross Profit Margin

      (Amounts in USD thousands, except percentages)

      (Unaudited)




      Three months ended March 31,



      2026


      2025

      Revenue


      $        21,688


      $        17,779

      Cost of revenue


      (6,939)


      (5,571)

      Gross profit


      $        14,749


      $        12,208

      Amortization of capitalized research and development expenses(3)


      1,602


      1,241

      Adjusted gross profit


      $        16,351


      $        13,449






      Gross profit margin


      68.0 %


      68.7 %

      Amortization of capitalized research and development expenses(3)


      7.4 %


      7.0 %

      Adjusted gross profit margin


      75.4 %


      75.7 %

      Notes to the Reconciliation of IFRS to Adjusted Financial Measures Tables

      1. Share-based compensation expense represents the cost of equity awards issued to our directors, officers, and employees. The fair value of awards is computed at the time the award is granted and is recognized over the vesting period of the award by a charge to the income statement and a corresponding increase in other reserves within equity. These expenses do not have a cash impact but remain a recurring expense for our business and represent an important part of our overall compensation strategy.
      2. Non-cash pension expense consists of the amount recognized in excess of actual contributions made to our defined pension plans to match actuarial expenses calculated for IFRS purposes. The difference represents a non-cash expense but remains a recurring expense for our business as we continue to make contributions to our plans for the foreseeable future.
      3. Amortization of capitalized research and development expenses consists of software development costs amortized using the straight-line method over an estimated life of five years. These expenses do not have a cash impact but remain a recurring expense generated over the course of our research and development initiatives.
      4. Amortization of intangible assets consists of costs related to intangible assets amortized over the course of their useful lives. These expenses do not have a cash impact, but we could continue to generate such expenses through future capital investments.
      5. Transaction costs consists of expenses incurred in connection with the Company's shelf registration statement and the ATM program.
      6. Litigation expenses consists of expenses related to the company's defense of lawsuits filed by Guardant Health.
      7. Social charges related to share-based compensation consist of payroll taxes and other social charges on share-based compensation awards. These expenses have been, and will continue to be for the foreseeable future, a recurring expense in the company's business.

      SOURCE SOPHiA GENETICS

      Modal title

      Also from this source

      SOPHiA GENETICS Reports Third Quarter 2026 Results

      SOPHiA GENETICS Reports Third Quarter 2026 Results

      SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the third quarter ended...

      SOPHiA GENETICS to Announce Financial Results for Third Quarter 2026 on November 3, 2026

      SOPHiA GENETICS to Announce Financial Results for Third Quarter 2026 on November 3, 2026

      SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for the third...

      More Releases From This Source

      Explore

      Biotechnology

      Biotechnology

      Computer & Electronics

      Computer & Electronics

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Computer Software

      Computer Software

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.